DUBLIN--(BUSINESS WIRE)--The "Market Spotlight: Myelodysplastic Syndrome (MDS)" report has been added to ResearchAndMarkets.com's offering.
This Market Spotlight report covers the myelodysplastic syndrome market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Approved drugs in the MDS space target DNA methyltransferase, BCR-ABL fusion protein, KIT/c-KIT, platelet-derived growth factor receptor, erythropoietin receptor, angiogenesis, and E3 ubiquitin ligase. The majority of approved therapies are administered via the intravenous route; however, a few products are available in oral and subcutaneous formulations.
- Approved drugs in the MDS space target DNA methyltransferase, BCR-ABL fusion protein, KIT/c-KIT, platelet-derived growth factor receptor, erythropoietin receptor, angiogenesis, and E3 ubiquitin ligase. The majority of approved therapies are administered via the intravenous route; however, a few products are available in oral and subcutaneous formulations.
- The majority of industry-sponsored drugs in active clinical development for MDS are in Phase II. Therapies in mid- and late-stage development for MDS focus on a wide variety of targets. The pipeline drugs in mid- to late-stage development for MDS are administered via the intravenous, intradermal, oral, subcutaneous, or topical route.
- High-impact upcoming events for drugs in the MDS space include topline Phase II trial results. There were 15 licensing and asset acquisition deals agreed during 2013-18. The largest deal during this period was the $935m exclusive licensing agreement in 2014 between Geron Corporation and Janssen Biotech to develop and commercialize Geron Corporation's imetelstat (a telomerase inhibitor) globally for oncology, including hematologic malignancies, and other human therapeutics uses.
- Revlimid's sales have ranked highest in the MDS space during 2012-16 and are forecast to remain the highest during the outlook period (2017-22).
- The clinical trials distribution across Phases I-IV indicates that the majority of trials for MDS have been in early and mid-phases of development, with 90% of trials in Phase I-II, and only 10% in Phase III-IV.
- The US has a substantial lead in the number of MDS clinical trials globally. Germany leads the major EU markets, while Japan has the top spot in Asia.
-
Celgene has the highest number of completed clinical trials for MDS,
with 78 completed trials. The company has also carried out the most
Phase II trials in MDS, followed by Sanofi, which has sponsored 37
Phase II trials.
For more information about this report visit https://www.researchandmarkets.com/research/t54lxj/global?w=4
